|
參考文獻
1. Organization WH: GLOBOCAN 2008 (IARC) Section of Cancer Information 2011,
4/7/2011.
2. Department of Health EY, R.O.C (Taiwan): 98 年度死因統計完整統計表. 2009.
3. Xue F, Willett WC, Rosner BA, Hankinson SE, Michels KB: Cigarette smoking and the
incidence of breast cancer. Arch Intern Med 2011, 171(2):125-133.
4. Park S, Bae J, Nam BH, Yoo KY: Aetiology of cancer in Asia. Asian Pac J Cancer Prev
2008, 9(3):371-380.
5. Smith SJ, Deacon JM, Chilvers CE: Alcohol, smoking, passive smoking and caffeine in
relation to breast cancer risk in young women. UK National Case-Control Study
Group. Br J Cancer 1994, 70(1):112-119.
6. Latif A, Hadfield KD, Roberts SA, Shenton A, Lalloo F, Black GC, Howell A, Evans DG,
Newman WG: Breast cancer susceptibility variants alter risks in familial disease. J
Med Genet 2010, 47(2):126-131.
7. Huang CS, Shen CY, Chang KJ, Hsu SM, Chern HD: Cytochrome P4501A1
polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese
women in Taiwan. Br J Cancer 1999, 80(11):1838-1843.
8. Wang K, Ye Y, Xu Z, Zhang X, Hou Z, Cui Y, Song Y: Interaction between
BRCA1/BRCA2 and ATM/ATR associate with breast cancer susceptibility in a
Chinese Han population. Cancer Genet Cytogenet 2010, 200(1):40-46.
9. del Valle J, Feliubadalo L, Nadal M, Teule A, Miro R, Cuesta R, Tornero E, Menendez M,
Darder E, Brunet J et al: Identification and comprehensive characterization of large
genomic rearrangements in the BRCA1 and BRCA2 genes. Breast Cancer Res Treat
2010, 122(3):733-743.
10. Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M: Genetic susceptibility to breast
cancer. Mol Oncol 2010, 4(3):174-191.
11. Kristensen VN, Borresen-Dale AL: SNPs associated with molecular subtypes of breast
cancer: on the usefulness of stratified Genome-wide Association Studies (GWAS) in
the identification of novel susceptibility loci. Mol Oncol 2008, 2(1):12-15.
12. Barnholtz-Sloan JS, Shetty PB, Guan X, Nyante SJ, Luo J, Brennan DJ, Millikan RC:
FGFR2 and other loci identified in genome-wide association studies are associated
with breast cancer in African-American and younger women. Carcinogenesis 2010,
31(8):1417-1423.
13. Kraft P, Haiman CA: GWAS identifies a common breast cancer risk allele among
BRCA1 carriers. Nat Genet 2010, 42(10):819-820.
14. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z,
Welch R, Hutchinson A et al: A genome-wide association study identifies alleles in
37
FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet
2007, 39(7):870-874.
15. Katoh M: Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 2008,
33(2):233-237.
16. Prentice RL, Huang Y, Hinds DA, Peters U, Pettinger M, Cox DR, Beilharz E, Chlebowski
RT, Rossouw JE, Caan B et al: Variation in the FGFR2 gene and the effects of
postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol
Biomarkers Prev 2009, 18(11):3079-3085.
17. Udler MS, Meyer KB, Pooley KA, Karlins E, Struewing JP, Zhang J, Doody DR,
MacArthur S, Tyrer J, Pharoah PD et al: FGFR2 variants and breast cancer risk:
fine-scale mapping using African American studies and analysis of chromatin
conformation. Hum Mol Genet 2009, 18(9):1692-1703.
18. Damasceno M: Bevacizumab for the first-line treatment of human epidermal growth
factor receptor 2-negative advanced breast cancer. Curr Opin Oncol 2011, 23
Suppl:S3-9.
19. Rhee J, Han SW, Cha Y, Ham HS, Kim HP, Oh DY, Im SA, Park JW, Ro J, Lee KS et al:
High serum TGF-alpha predicts poor response to lapatinib and capecitabine in
HER2-positive breast cancer. Breast Cancer Res Treat 2011, 125(1):107-114.
20. Kim JY, Kim CH, Stratford IJ, Patterson AV, Hendry JH: The bioreductive agent RH1
and gamma-irradiation both cause G2/M cell cycle phase arrest and polyploidy in a
p53-mutated human breast cancer cell line. Int J Radiat Oncol Biol Phys 2004,
58(2):376-385.
21. Feeney GP, Errington RJ, Wiltshire M, Marquez N, Chappell SC, Smith PJ: Tracking the
cell cycle origins for escape from topotecan action by breast cancer cells. Br J Cancer
2003, 88(8):1310-1317.
22. Nagasawa H, Keng P, Maki C, Yu Y, Little JB: Absence of a radiation-induced first-cycle
G1-S arrest in p53+ human tumor cells synchronized by mitotic selection. Cancer Res
1998, 58(9):2036-2041.
23. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE,
Nordestgaard BG, Axelsson CK, Arias JI et al: Heterogeneity of breast cancer
associations with five susceptibility loci by clinical and pathological characteristics.
PLoS Genet 2008, 4(4):e1000054.
24. Milne RL, Benitez J, Nevanlinna H, Heikkinen T, Aittomaki K, Blomqvist C, Arias JI,
Zamora MP, Burwinkel B, Bartram CR et al: Risk of estrogen receptor-positive and
-negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl
Cancer Inst 2009, 101(14):1012-1018.
25. Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A,
Peterlongo P, Manoukian S, Peissel B et al: Common alleles at 6q25.1 and 1p11.2 areassociated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum
38
Mol Genet 2011.
26. Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Sinilnikova OM, Beesley J, Chen X,
McGuffog L, Healey S, Couch FJ et al: Genetic variation at 9p22.2 and ovarian cancer
risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2011,
103(2):105-116.
27. Pilato B, Martinucci M, Danza K, Pinto R, Petriella D, Lacalamita R, Bruno M, Lambo R,
D''Amico C, Paradiso A et al: Mutations and polymorphic BRCA variants transmission
in breast cancer familial members. Breast Cancer Res Treat 2011, 125(3):651-657.
28. Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding
YC, Rebbeck TR, Weitzel JN, Lynch HT et al: Common breast cancer susceptibility
alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers:
implications for risk prediction. Cancer Res 2010, 70(23):9742-9754.
29. Hou MF, Tsai KB, Fan HM, Wang CY, Lin WC, Liu CS, Lin HJ, Chai CY, Fu OY, Li SS et
al: Familial breast cancer in southern Taiwan. Kaohsiung J Med Sci 2000,
16(8):414-421.
30. Balleine RL, Provan PJ, Pupo GM, Pathmanathan N, Cummings M, Farshid G, Salisbury
EL, Bilous AM, Byth K, Mann GJ: Familial concordance of breast cancer pathology as
an indicator of genotype in multiple-case families. Genes Chromosomes Cancer 2010,
49(12):1082-1094.
31. Tondel M, Lindgren P, Hellstrom L, Lofman O, Fredrikson M: Risk of malignancies in
relation to terrestrial gamma radiation in a Swedish population cohort. Sci Total
Environ 2011, 409(3):471-477.
32. Ferris DG, Golden NH, Petry LJ, Litaker MS, Nackenson M, Woodward LD: Effectiveness
of breast self-examination prompts on oral contraceptive packaging. J Fam Pract 1996,
42(1):43-48.
33. Morabia A, Szklo M, Stewart W, Schuman L, Thomas DB: Consistent lack of association
between breast cancer and oral contraceptives using either hospital or neighborhood
controls. Prev Med 1993, 22(2):178-186.
34. Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged
less than 50 years. Breast Cancer Res Treat 2008, 109(1):67-75.
35. Gram IT, Braaten T, Terry PD, Sasco AJ, Adami HO, Lund E, Weiderpass E: Breast cancer
risk among women who start smoking as teenagers. Cancer Epidemiol Biomarkers Prev
2005, 14(1):61-66.
36. Schutze M, Boeing H, Pischon T, Rehm J, Kehoe T, Gmel G, Olsen A, Tjonneland AM,
Dahm CC, Overvad K et al: Alcohol attributable burden of incidence of cancer in eight
European countries based on results from prospective cohort study. BMJ 2011,
342:d1584.
37. Cabanes A, Pastor-Barriuso R, Garcia-Lopez M, Pedraz-Pingarron C, Sanchez-Contador C,
Vazquez Carrete JA, Moreno MP, Vidal C, Salas D, Miranda-Garcia J et al: Alcohol,tobacco, and mammographic density: a population-based study. Breast Cancer Res
Treat 2011.
38. de Juan I, Esteban E, Palanca S, Barragan E, Bolufer P: High-resolution melting analysis
for rapid screening of BRCA1 and BRCA2 Spanish mutations. Breast Cancer Res Treat
2009, 115(2):405-414.
39. Wittwer CT: High-resolution DNA melting analysis: advancements and limitations.
Hum Mutat 2009, 30(6):857-859.
40. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA: Polygenic
susceptibility to breast cancer and implications for prevention. Nat Genet 2002,
31(1):33-36.
41. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing
JP, Morrison J, Field H, Luben R et al: Genome-wide association study identifies novel
breast cancer susceptibility loci. Nature 2007, 447(7148):1087-1093.
42. Dillon C, Spencer-Dene B, Dickson C: A crucial role for fibroblast growth factor
signaling in embryonic mammary gland development. J Mammary Gland Biol
Neoplasia 2004, 9(2):207-215.
43. Grose R, Dickson C: Fibroblast growth factor signaling in tumorigenesis. Cytokine
Growth Factor Rev 2005, 16(2):179-186.
44. Zhong H, Prentice RL: Correcting "winner''s curse" in odds ratios from genomewide
association findings for major complex human diseases. Genet Epidemiol 2010,
34(1):78-91.
45. Zheng W, Cai Q, Signorello LB, Long J, Hargreaves MK, Deming SL, Li G, Li C, Cui Y,
Blot WJ: Evaluation of 11 breast cancer susceptibility loci in African-American women.
Cancer Epidemiol Biomarkers Prev 2009, 18(10):2761-2764.
46. Zhang J, Qiu LX, Wang ZH, Leaw SJ, Wang BY, Wang JL, Cao ZG, Gao JL, Hu XC:
Current evidence on the relationship between three polymorphisms in the FGFR2
gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010,
124(2):419-424.
47. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK,
Fertuck KC, Hall GF et al: Genome-wide analysis of estrogen receptor binding sites.
Nat Genet 2006, 38(11):1289-1297.
48. Garcia-Closas M, Chanock S: Genetic susceptibility loci for breast cancer by estrogen
receptor status. Clin Cancer Res 2008, 14(24):8000-8009.
49. Song H, Ramus SJ, Kjaer SK, DiCioccio RA, Chenevix-Trench G, Pearce CL, Hogdall E,
Whittemore AS, McGuire V, Hogdall C et al: Association between invasive ovarian
cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide
association study. Hum Mol Genet 2009, 18(12):2297-2304.
50. Chen MB, Wu XY, Shen W, Wei MX, Li C, Cai B, Tao GQ, Lu PH: Association between
polymorphisms of trinucleotide repeat containing 9 gene and breast cancer risk:
40
evidence from 62,005 subjects. Breast Cancer Res Treat 2011, 126(1):177-183.
51. Ruiz-Narvaez EA, Rosenberg L, Cozier YC, Cupples LA, Adams-Campbell LL, Palmer JR:
Polymorphisms in the TOX3/LOC643714 locus and risk of breast cancer in
African-American women. Cancer Epidemiol Biomarkers Prev 2010, 19(5):1320-1327.
52. McInerney N, Colleran G, Rowan A, Walther A, Barclay E, Spain S, Jones AM, Tuohy S,
Curran C, Miller N et al: Low penetrance breast cancer predisposition SNPs are site
specific. Breast Cancer Res Treat 2009, 117(1):151-159.
53. Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T,
Simard J, Spurdle AB, Beesley J, Chen X et al: Common variants in LSP1, 2q35 and
8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol
Genet 2009, 18(22):4442-4456.
54. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, Masson G,
Jakobsdottir M, Thorlacius S, Helgason A et al: Common variants on chromosomes 2q35
and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet
2007, 39(7):865-869.
55. Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, Hankinson SE,
Hutchinson A, Wang Z, Yu K et al: A multistage genome-wide association study in
breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat
Genet 2009, 41(5):579-584.
56. Mavaddat N, Pharoah PD, Blows F, Driver KE, Provenzano E, Thompson D, Macinnis RJ,
Shah M, Easton DF, Antoniou AC: Familial relative risks for breast cancer by
pathological subtype: a population-based cohort study. Breast Cancer Res 2010,
12(1):R10.
57. Reeves GK, Travis RC, Green J, Bull D, Tipper S, Baker K, Beral V, Peto R, Bell J,
Zelenika D et al: Incidence of breast cancer and its subtypes in relation to individual
and multiple low-penetrance genetic susceptibility loci. JAMA 2010, 304(4):426-434.
|